Asset Details
Do you wish to reserve the book?
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Do you wish to request the book?
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
2024
Overview
Background
Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of long-term CRCI. We evaluated associations between inflammatory markers assessed at diagnosis of breast cancer and CRCI two years afterwards.
Methods
Newly diagnosed stage I-III patients with breast cancer from the French CANTO-Cog (Cognitive sub-study of CANTO, NCT01993498) were included at diagnosis (baseline). Serum inflammatory markers (IL-2, IL-4, IL-6, IL-8, IL-10, TNFα, CRP) were assessed at baseline. Outcomes at year 2 post-baseline included overall cognitive impairment (≥ 2 impaired domains) and the following domains: episodic memory, working memory, attention, processing speed, and executive functions. Multivariable logistic regression models evaluated associations between markers and outcomes, controlling for age, education, and baseline cognitive impairment.
Results
Among 200 patients, the mean age was 54 ± 11 years, with 127 (64%) receiving chemotherapy. Fifty-three (27%) patients had overall cognitive impairment at both timepoints. Overall cognitive impairment at year 2 was associated with high (> 3 mg/L) baseline CRP (OR = 2.84, 95%CI: 1.06–7.64,
p
= 0.037). In addition, associations were found between high CRP and processing speed impairment (OR = 2.47, 95%CI:1.05–5.87,
p
= 0.039), and between high IL-6 and episodic memory impairment (OR = 5.50, 95%CI:1.43–36.6,
p
= 0.010).
Conclusions
In this cohort, high levels of CRP and IL-6 assessed at diagnosis were associated with overall CRCI, processing speed and episodic memory impairments two years later. These findings suggest a potential inflammatory basis for long-term CRCI. CRP may represent an easily measurable marker in clinical settings and be potentially used to screen patients at greater risk of persistent CRCI.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Aged
/ Analysis
/ Anxiety
/ Biomedical and Life Sciences
/ Breast Neoplasms - complications
/ Breast Neoplasms - diagnosis
/ C-Reactive Protein - analysis
/ C-Reactive Protein - metabolism
/ Cancer
/ Cancer-related cognitive impairment
/ Cognitive Dysfunction - blood
/ Cognitive Dysfunction - diagnosis
/ Cognitive Dysfunction - etiology
/ Female
/ Humans
/ Memory
/ Oncology
/ Patients
